Briefing
LBA8 IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
Among 250 eligible ctDNA-positive patients after cystectomy, adjuvant atezolizumab improved investigator-assessed DFS versus placebo (median 9.9 vs 4.8 months; HR 0.64, 95% CI 0.47-0.87; P=0.0047) and OS (median 32.8 vs 21.1 months; HR 0.59, 95% CI 0.39-0.90; P=0.0131). In 357 patients who remained ctDNA-negative, DFS was 95.4% at the end of 1-year monitoring and 88.4% at 2 years.
- Design: LBA
- n: 761 enrolled in surveillance; 250 ctDNA-positive patients randomized (167 atezolizumab, 83 placebo); 357 persistently ctDNA-negative
- Assay: not named in the abstract